Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Relief Therapeutics Holding's EV-to-OCF or its related term are showing as below:
RLFTF'
s EV-to-OCF Range Over the Past 10 Years
Min: -1931.03 Med: -4.81 Max: -0.03
Current: -7.74
During the past 13 years, the highest EV-to-OCF of Relief Therapeutics Holding was -0.03. The lowest was -1931.03. And the median was -4.81.
RLFTF's EV-to-OCF is not ranked
in the Biotechnology industry.
Industry Median: -3.48
vs RLFTF: -7.74
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Relief Therapeutics Holding's PE Ratio (TTM) for today is calculated as:
Relief Therapeutics Holding's share price for today is $0.30956.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Relief Therapeutics Holding's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2025 was $-1.563.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Relief Therapeutics Holding EV-to-OCF Related Terms
Relief Therapeutics Holding EV-to-OCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Relief Therapeutics Holding's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Relief Therapeutics Holding EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Relief Therapeutics Holding's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Relief Therapeutics Holding's EV-to-OCF falls into.
Relief Therapeutics Holding's current Enterprise Value is $34.15 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Relief Therapeutics Holding's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2025 was $-4.34 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Relief Therapeutics Holding (RLFTF) has a EV-to-OCF of -7.86 as of Aug. 09, 2026.
Is Relief Therapeutics Holding's EV-to-OCF too high?
Relief Therapeutics Holding's current EV-to-OCF is -7.86. Overall, Relief Therapeutics Holding has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Relief Therapeutics Holding's EV-to-OCF compare to KTTA and OSRH?
Relief Therapeutics Holding's EV-to-OCF of -7.86 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Relief Therapeutics Holding's current EV-to-OCF is -7.86. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Relief Therapeutics Holding stock overvalued right now?
Relief Therapeutics Holding (RLFTF) has a current EV-to-OCF of -7.86. The stock's GF Value™ is $0.65, compared to a current price of $0.31 — trading 52.4% below its estimated fair value. The current EV-to-OCF is -7.86. Relief Therapeutics Holding's overall GF Score™ is 31/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Relief Therapeutics Holding (RLFTF), the current EV-to-OCF is -7.86 as of Aug. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Relief Therapeutics Holding (RLFTF) Overvalued in 2026?
Based on GuruFocus' analysis, Relief Therapeutics Holding stock appears to be undervalued.
The current stock price of $0.31 is trading 52.4% below its estimated GF Value™ of $0.65.
Key valuation signals for RLFTF:
EV-to-OCF: -7.86
GF Value™: $0.65 vs. price of $0.31 (52.4% below fair value)
No single metric tells the full story. See the RLFTF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Relief Therapeutics Holding SA is engaged in the research, development, and commercialization of biopharmaceutical products. It mainly develops drugs of natural human origin. It has a focus on commercial products, and the development program pipeline is focused on three main areas: rare genetic, metabolic disorders, rare connective tissue disorders, and rare lung diseases. Its pipeline includes various drug candidates in their different stages of development, such as RLF-TD011 and RLF-100, among others. It also has commercial legacy products like Cambia, Setofilm, Voltadol, and Voltfast, among others. Geographically, the company generates a majority of its revenue from Europe (excluding Switzerland) and the rest from North America, Switzerland, and the rest of the world.
31GF Score
Get the complete analysis for RLFTF
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RLFTF has been successfully added to your 
